GCK-MODY leads to stable and mild fasting hyperglycemia due to reduced glucokinase enzyme activity and typically does not require pharmacologic treatment, whereas HNF1A-MODY and HNF4A-MODY are associated with progressive β-cell dysfunction and are often highly responsive to sulfonylurea therapy [1, 9]. Here, HNF1A is linked to MODY.